Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1988 Nov-Dec;40(6):603-11.

Substituted ergolines: potential antipsychotics with unique profile. II. Neurochemical characterization

Affiliations
  • PMID: 2479935

Substituted ergolines: potential antipsychotics with unique profile. II. Neurochemical characterization

F Auth et al. Pol J Pharmacol Pharm. 1988 Nov-Dec.

Abstract

A series of lumilysergol and lysergol derivatives were studied with a number of neurochemical methods. The compounds investigated showed heterogenous profiles on receptor binding tests. They were mostly active on D-2 receptors, but some alpha-1, alpha-2 and 5-HT-2 affinity could also be demonstrated. None of the drugs showed remarkable D-1 activities tested on basal and DA-stimulated adenylate cyclase (AC) enzyme in vitro. On the basis of the effects of the drugs on the mouse whole brain monoamine neurotransmitter and metabolite levels and neurotransmitter biosynthesis rates along with the receptor binding data we conclude that their actions are mainly related to the central dopaminergic system(s). The 2-halo-lumilysergole derivatives were less potent than the 2-halo-lysergoles with respect to their dopaminergic actions. We found the substitution at position 8 to be substantial to achieve agonistic or antagonistic properties, and, interestingly, 2,8-dihalo-lysergoles have proven to be DA agonists. The neurochemical findings are in good agreement with the behavioral results presented in the accompanying paper. We confirmed the behavioral data in that there are two subgroups among 2-halo-lysergoles possessing antipsychotic activity with opposite effects on DA receptors.

PubMed Disclaimer

MeSH terms